EU court’s finding against executive’s handling of text message exchange between Ursula von der Leyen and Pfizer CEO will ...

Pfizer Inc. and Albert Bourla got the upper hand in an early skirmish against Starboard Value LP — but the drugmaker and its embattled chief executive face a long war against an activist that ...

Pfizer Inc. CEO Albert Bourla is set to meet with activist investor Starboard Value amid growing pressure to revitalize the pharmaceutical giant's struggling share price and refine its strategic ...

When a novel coronavirus struck in early 2020, Pfizer’s chief executive, Dr. Albert Bourla, saw an opportunity to help save the world. He pushed the drugmaker to deliver a Covid-19 vaccine at ...

It's not clear yet if one is needed. Bourla said Pfizer is also hoping to make a vaccine that will protect against Omicron and all other variants of SARS-CoV-2 -- the virus that causes Covid-19.

Plus: All the news and watercooler chat from Fortune. Good morning. Pfizer’s Albert Bourla has become a fixture among Fortune 500 CEOs, having run the pharma giant since 2018.

In an attempt to save costs, Pfizer in May revealed a “multi-year program” to cut its cost of goods sold, which should result in $1.5 billion in savings by the end of 2027 starting in 2025.

Read was Pfizer's (PFE) chief executive officer from 2010 to 2018 and picked Pfizer's current CEO Albert Bourla as his successor. D’Amelio was Pfizer's chief financial officer from 2007 to 2021.

Pfizer Inc. (NYSE: PFE) Goldman Sachs 45th Annual Global Healthcare Conference June 10, 2024 11:20 AM ET Company Participants Albert Bourla - Chairman and CEO Conference Call Participants Chris ...

Like his Big Pharma peers, Pfizer (PFE) CEO Albert Bourla is waiting for the US government to finalize its decision on whether to place a 25% tariff on pharmaceutical imports. To be sure, he said ...

Pfizer reaffirmed $10–$15 billion for business development, with focus on immunology and cardiometabolic expansion. CEO Bourla says national security concerns are central to U.S. drug ...